Latest Breaking News On - ஜான் சேஜர்லைஸ் - Page 1 : comparemela.com

Indigenous construction companies in Saskatchewan now have collective voice

New poll says majority of Indigenous people support resource development

New poll says majority of Indigenous people support resource development - Canadian Mining Journal

Xencor begins dosing in Phase I trial of autoimmune disease treatment

Xencor begins dosing in Phase I trial of autoimmune disease treatment 29 Apr 2021 (Last Updated April 29th, 2021 17:28) Xencor has dosed the first subject in a Phase I clinical study of an engineered Interleukin-2 (IL-2) Fc cytokine, XmAb564, for the treatment of patients with autoimmune diseases.  Share Article The study will assess the safety, tolerability and pharmacokinetics of subcutaneously administered XmAb564 in healthy adult subjects. Credit: Edgar Y Pardo from Pixabay. Xencor has dosed the first subject in a Phase I clinical study of an engineered Interleukin-2 (IL-2) Fc cytokine, XmAb564, for the treatment of patients with autoimmune diseases. XmAb564 is a monovalent IL-2-Fc fusion protein that can selectively stimulate and expand regulatory T cells (Tregs) for treating autoimmune diseases.

Xencor Presents Positive Data For XmAb Antibodies Program Against Cancer